Read more VitroScan featured in Oncologie Up-to-date magazine

6 January 2026

VitroScan, known for its ex vivo 3D micro-tumor testing platform, has been highlighted in the latest issue of Oncologie Up-to-date, the Dutch medical scientific news magazine that reports on current developments in oncology .

Read more

Read more Meet VitroScan!

1 November 2025

In this video, Willemijn Vader explains how our ChemoPredict platform supports better treatment decisions.

Read more

Read more VitroScan will be pitching at the Dutch Life Sciences Day investors forum

31 October 2025

Meet VitroScan at the Dutch Life Sciences Conference 2025 where Willemijn Vader will be pitching at the investors forum.

Read more

Read more Info Sheet ADC efficacy assessment

1 December 2025

Download our Info sheet on ADC efficacy assessment in VitroScan's ex vivo micro-tumor platform

Read more

Read more Info Sheet Bispecific antibody testing

1 December 2025

Download our Info sheet on bispecific antibody efficacy assessment in VitroScan's ex vivo micro-tumor platform

Read more

Read more Our latest publication at a glance!

1 October 2025

Download our Info sheet on the latest VitroScan publication highlighting the predictive value of our platform

Read more

Read more VitroScan at SITC 2025

5 November 2025

Download our poster: Ex vivo micro-tumor testing identifies patient-specific anti-tumor immune responses to T cell engager ubamatamab

Read more

Read more VitroScan at ENA 2025

22 October 2025

Download our poster: Bispecific antibody ubamatamab induces patient-specific anti-tumor immune responses in an ex vivo platform for ovarian cancer

Read more

Read more VitroScan at ESMO 2025

17 October 2025

Download our poster: Chemo Sensitivity Score using an ex vivo 3D micro-tumor testing platform to predict clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer

Read more

Read more Koedoot et al., npj Precision Oncology, 2025

30 August 2025

Publication of our study showing that VitroScan's 3D ex vivo micro-tumor testing platform can accurately predict whether an ovarian cancer patient will respond to chemotherapy.

Read more